10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Cervical Cancer
2 articles
Gut Microbiome: A New Frontier in Predicting Immunotherapy Outcomes for Gynecologic Cancers
Study reveals gut bacteria's role in immunotherapy outcomes for cervical and endometrial cancer patients.
Immunotherapy Breakthrough: Pembrolizumab Boosts Survival in Advanced Cervical Cancer
Pembrolizumab plus chemoradiotherapy significantly improves survival in high-risk cervical cancer patients.